AR096854A1 - Composición farmacéutica para una liberación sostenida de lanreotide - Google Patents
Composición farmacéutica para una liberación sostenida de lanreotideInfo
- Publication number
- AR096854A1 AR096854A1 ARP140102537A ARP140102537A AR096854A1 AR 096854 A1 AR096854 A1 AR 096854A1 AR P140102537 A ARP140102537 A AR P140102537A AR P140102537 A ARP140102537 A AR P140102537A AR 096854 A1 AR096854 A1 AR 096854A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- lanreotide
- sustained release
- acid
- composition according
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 8
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 title abstract 5
- 229960002437 lanreotide Drugs 0.000 title abstract 5
- 108010021336 lanreotide Proteins 0.000 title abstract 5
- 238000013268 sustained release Methods 0.000 title abstract 4
- 239000012730 sustained-release form Substances 0.000 title abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003002 pH adjusting agent Substances 0.000 abstract 2
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
Abstract
Composición farmacéutica para la liberación sostenida de lanreotide, en particular para una liberación sostenida compatible con tratamientos terapéuticos de por lo menos 2 meses de duración. Las composiciones farmacéuticas son de particular utilidad para el tratamiento de las enfermedades para las cuales está indicado el lanreotide. Reivindicación 1: Composición farmacéutica para la liberación sostenida de un ingrediente activo durante por lo menos 2 meses, caracterizada porque comprende: lanreotide como ingrediente activo, un cosolvente hidrosoluble y agua, donde el pH varía en un rango entre 4,0 y 7,5. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el lanreotide está presente a una concentración que varía en un rango entre 35 y 55% en peso con relación al peso total de la composición. Reivindicación 7: La composición farmacéutica de acuerdo con la reivindicación 6, caracterizada porque comprende un modificador del pH que es diferente del cosolvente. Reivindicación 8: La composición farmacéutica de acuerdo con la reivindicación 5 a 7, caracterizada porque el modificador del pH se selecciona entre ácido acético, ácido cítrico, ácido láctico, ácido fosfórico, ácido clorhídrico, ácido esteárico y ácido pamoico. Reivindicación 15: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque es para su uso en el tratamiento de acromegalia o NET.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13290156.2A EP2823808A1 (en) | 2013-07-09 | 2013-07-09 | Pharmaceutical composition for a sustained release of lanreotide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096854A1 true AR096854A1 (es) | 2016-02-03 |
Family
ID=48832841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102537A AR096854A1 (es) | 2013-07-09 | 2014-07-08 | Composición farmacéutica para una liberación sostenida de lanreotide |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10543249B2 (es) |
| EP (2) | EP2823808A1 (es) |
| JP (2) | JP2016523945A (es) |
| KR (1) | KR102232410B1 (es) |
| CN (1) | CN105392470A (es) |
| AR (1) | AR096854A1 (es) |
| AU (1) | AU2014289332B2 (es) |
| CA (1) | CA2917098A1 (es) |
| DK (1) | DK3035912T3 (es) |
| EA (1) | EA034224B1 (es) |
| ES (1) | ES2928676T3 (es) |
| HU (1) | HUE060497T2 (es) |
| IL (1) | IL243027A0 (es) |
| MX (1) | MX367926B (es) |
| PL (1) | PL3035912T3 (es) |
| PT (1) | PT3035912T (es) |
| SG (1) | SG11201510698QA (es) |
| TW (1) | TWI715520B (es) |
| UA (1) | UA116569C2 (es) |
| WO (1) | WO2015004125A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109381695A (zh) * | 2017-08-09 | 2019-02-26 | 武汉武药科技有限公司 | 一种门冬氨酸帕瑞肽注射液及其制备方法和用途 |
| FR3079421B1 (fr) * | 2018-03-28 | 2024-11-15 | Edix Sa | Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide |
| US20210121517A1 (en) | 2019-10-24 | 2021-04-29 | Sun Pharmaceutical Industries Limited | Stable parenteral dosage form of cetrorelix acetate |
| LU101974B1 (en) | 2020-08-07 | 2022-02-07 | Pharmathen Sa | Process and apparatus for preparing viscous pharmaceutical formulations |
| EP4445950A3 (en) | 2020-08-07 | 2024-12-11 | Pharmathen S.A. | Process and apparatus for preparing viscous pharmaceutical formulations |
| GR1010059B (el) * | 2020-08-10 | 2021-08-13 | Φαρματεν Α.Β.Ε.Ε. | Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων |
| WO2023092148A1 (en) * | 2021-11-22 | 2023-05-25 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
| WO2026006394A1 (en) * | 2024-06-26 | 2026-01-02 | Loyal Animal Health, Inc. | Somatostatin analogs and compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US271189A (en) * | 1883-01-23 | beals | ||
| CN101590011A (zh) * | 1994-09-02 | 2009-12-02 | 科学研究与运用咨询公司 | 肽从药物组合物中的持续释放 |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| EP0909175B1 (en) * | 1996-07-03 | 2003-06-04 | Alza Corporation | Non-aqueous protic peptide formulations |
| FR2762319A1 (fr) | 1997-04-18 | 1998-10-23 | Pharma Biotech | Microcapsules presentant une liberation prolongee et leur procede de preparation |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| IT1318539B1 (it) * | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| CN1415378A (zh) | 2002-10-22 | 2003-05-07 | 南京长澳医药科技有限公司 | 生长抑素冻干粉针及其制备工艺 |
| WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
| JP4951344B2 (ja) * | 2004-08-24 | 2012-06-13 | 第一三共株式会社 | 生理活性ペプチド液状製剤 |
| CA2590696A1 (en) * | 2004-12-15 | 2006-06-22 | Qlt Usa, Inc. | Sustained delivery formulations of octreotide compounds |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| KR100983746B1 (ko) * | 2005-01-14 | 2010-09-24 | 카무러스 에이비 | 소마토스타틴 유사 제형 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| FI120057B (fi) * | 2007-07-13 | 2009-06-15 | Andritz Oy | Laite ja menetelmä lipeäruiskun puhdistamiseksi ja jäähdyttämiseksi |
| WO2009033741A2 (en) | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s) |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| RU2541104C2 (ru) * | 2008-01-30 | 2015-02-10 | Новартис Аг | Препаративная форма с замедленным высвобождением, содержащая октреотид и три линейных полимера поли(лактид-со-гликолида) |
| RU2504360C2 (ru) | 2008-08-12 | 2014-01-20 | Новартис Аг | Фармацевтические композиции |
| EP2168983A1 (fr) | 2008-09-30 | 2010-03-31 | Ipsen Pharma | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
| US20110250243A1 (en) * | 2008-12-15 | 2011-10-13 | Thomas Kissel | Nanoparticle compositions |
| US20120172650A1 (en) * | 2009-03-18 | 2012-07-05 | Laurence Katznelson | Use of somatostatin or an analogue thereof in combination with external radiation therapy |
| JP6029472B2 (ja) * | 2010-01-13 | 2016-11-24 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． | ソマトスタチン類似体（アナログ）の持続的放出のための医薬組成物の製造方法 |
| CN104093399B (zh) * | 2011-12-05 | 2018-03-13 | 卡穆鲁斯公司 | 鲁棒性控释肽制剂 |
-
2013
- 2013-07-09 EP EP13290156.2A patent/EP2823808A1/en not_active Ceased
-
2014
- 2014-07-08 HU HUE14736812A patent/HUE060497T2/hu unknown
- 2014-07-08 US US14/903,010 patent/US10543249B2/en active Active
- 2014-07-08 EP EP14736812.0A patent/EP3035912B1/en active Active
- 2014-07-08 DK DK14736812.0T patent/DK3035912T3/da active
- 2014-07-08 PL PL14736812.0T patent/PL3035912T3/pl unknown
- 2014-07-08 SG SG11201510698QA patent/SG11201510698QA/en unknown
- 2014-07-08 PT PT147368120T patent/PT3035912T/pt unknown
- 2014-07-08 AR ARP140102537A patent/AR096854A1/es not_active Application Discontinuation
- 2014-07-08 CN CN201480038507.4A patent/CN105392470A/zh active Pending
- 2014-07-08 EA EA201690191A patent/EA034224B1/ru not_active IP Right Cessation
- 2014-07-08 WO PCT/EP2014/064586 patent/WO2015004125A1/en not_active Ceased
- 2014-07-08 JP JP2016524794A patent/JP2016523945A/ja active Pending
- 2014-07-08 TW TW103123446A patent/TWI715520B/zh active
- 2014-07-08 CA CA2917098A patent/CA2917098A1/en not_active Abandoned
- 2014-07-08 MX MX2016000294A patent/MX367926B/es active IP Right Grant
- 2014-07-08 KR KR1020167003036A patent/KR102232410B1/ko active Active
- 2014-07-08 AU AU2014289332A patent/AU2014289332B2/en active Active
- 2014-07-08 ES ES14736812T patent/ES2928676T3/es active Active
- 2014-08-07 UA UAA201601113A patent/UA116569C2/uk unknown
-
2015
- 2015-12-21 IL IL243027A patent/IL243027A0/en unknown
-
2019
- 2019-02-25 JP JP2019032085A patent/JP6811270B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160151447A1 (en) | 2016-06-02 |
| UA116569C2 (uk) | 2018-04-10 |
| ES2928676T3 (es) | 2022-11-21 |
| EP3035912B1 (en) | 2022-08-31 |
| KR20160030232A (ko) | 2016-03-16 |
| WO2015004125A1 (en) | 2015-01-15 |
| HUE060497T2 (hu) | 2023-03-28 |
| EP2823808A1 (en) | 2015-01-14 |
| KR102232410B1 (ko) | 2021-03-29 |
| JP2019073564A (ja) | 2019-05-16 |
| PL3035912T3 (pl) | 2022-12-05 |
| TWI715520B (zh) | 2021-01-11 |
| JP2016523945A (ja) | 2016-08-12 |
| EA201690191A1 (ru) | 2016-06-30 |
| MX367926B (es) | 2019-09-12 |
| US10543249B2 (en) | 2020-01-28 |
| EP3035912A1 (en) | 2016-06-29 |
| EA034224B1 (ru) | 2020-01-20 |
| SG11201510698QA (en) | 2016-01-28 |
| TW201536346A (zh) | 2015-10-01 |
| IL243027A0 (en) | 2016-02-29 |
| AU2014289332B2 (en) | 2019-07-11 |
| MX2016000294A (es) | 2016-04-28 |
| JP6811270B2 (ja) | 2021-01-13 |
| PT3035912T (pt) | 2022-10-26 |
| DK3035912T3 (da) | 2022-10-03 |
| CA2917098A1 (en) | 2015-01-15 |
| CN105392470A (zh) | 2016-03-09 |
| AU2014289332A1 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| DOP2012000299A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CL2017002792A1 (es) | Derivados de ciclohexano sustituido con amido | |
| BRPI1002601E2 (pt) | composição nanoestruturada de uso veterinário para administração de fármacos | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| HN2010002518A (es) | Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina | |
| UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| BR112012033755A2 (pt) | composições e métodos antissépticos estáveis | |
| MX2012005013A (es) | Pterostilbeno (peter) para su uso en la prevencion y/el tratamiento de enfermedades, daños o lesiones de la piel. | |
| SV2011003907A (es) | Composiciones antimicrobianas | |
| UY33634A (es) | ?combinaciones sinérgicas de triazoles, estrobirulinas y benzimidazoles, usos, formulaciones, procedimientos de producción y aplicaciones utilizando las mismas?. | |
| CL2014000050A1 (es) | Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson. | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| BR112013021889A2 (pt) | método para a indução de resistência a doenças em plantas | |
| AR102780A1 (es) | Composiciones farmacéuticas, su preparación y sus usos | |
| UY35848A (es) | Tienopirimidinas | |
| EP4302825A3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| CO6761349A2 (es) | Proteína antimicrobiana | |
| UY33633A (es) | ?combinación sinérgica de abamectina y bifentrina, su proceso de preparación y uso, y método utilizando la misma" | |
| BR112015002984A2 (pt) | composição, vacina para proteger um animal contra uma infecção com bactérias leptospira, e, uso de ácido cítrico. | |
| DOP2013000004A (es) | Agentes terapeuticos 976 | |
| MX2013001040A (es) | Composiciones para el tratamiento de la infestacion por parasitos del corazon. | |
| UY35600A (es) | "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" | |
| AR071350A1 (es) | Agentes para el tratamiento y o la prevencion del tizon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |